News

Article

FDA Grants Fast Track Designation for Decompensated Heart Failure Drug

The drug is formulated to improve cardiac contractility with a reduced effect on heart rate, blood pressure, and myocardial oxygen consumption while potentially avoiding adverse events associated with current inotrope therapies.

On Jan. 16, 2020, Arena Pharmaceuticals announced FDA granted fast track designation for APD418, its β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope for the treatment of decompensated heart failure (DHF).

Discovered and developed internally by Arena, APD418 is formulated to improve cardiac contractility with a reduced effect on heart rate, blood pressure, and myocardial oxygen consumption while potentially avoiding adverse events associated with current inotrope therapies, according to an Arena press release.

“With approximately 10 million DHF patient hospital visits expected in the [United States] by 2025 and few viable treatment options, we believe that APD418 has the potential to make a significant impact for these patients," said Chris Cabell, MD, Arena's senior vice-president and chief medical officer, in the press release. "We are pleased with the [f]ast [t]rack designation and look forward to advancing this program as part of our cardiovascular focus."

Source: Arena

 

 

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content